journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Biological Therapy

journal
https://www.readbyqxmd.com/read/27927023/novel-strategies-for-improving-hematopoietic-reconstruction-after-allogeneic-hematopoietic-stem-cell-transplantation-or-intensive-chemotherapy
#1
Frédéric Baron, Arnon Nagler
High-dose conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT) as well as intensive poly-chemotherapy for acute myeloid leukemia (AML) induce prolonged periods of neutropenia. The duration of the neutropenia is particularly long following umbilical cord blood transplantation (UCBT). Areas covered: After briefly reviewing the impact of hematopoietic growth factors administration to hasten hematologic reconstitution after allo-HCT or intensive AML chemotherapy, this article summarizes recent approaches that have been investigated to prompt hematologic reconstruction after UCBT or intensive AML chemotherapy...
December 8, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27892722/present-and-future-dna-vaccines-for-chronic-hepatitis-b-treatment
#2
Lucyna Cova
With at least 240 million hepatitis B virus (HBV) carriers worldwide, being at a high risk of cirrhosis and hepatocellular carcinoma (HCC), chronic hepatitis B remains a major public health issue. Because current antiviral treatments are only virostatic, there is an urgent need for the development of innovative anti-HBV strategies leading to the functional cure. In this context, DNA-based vaccines appear as a promising approach. Area covered: In this review, the authors summarize the pertinent features of DNA vaccines for chronic hepatitis B therapy...
November 28, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27817214/antibody-therapeutics-for-treating-prostate-cancer-where-are-we-now-and-what-comes-next
#3
Panagiotis J Vlachostergios, Giuseppe Galletti, Jessica Palmer, Linda Lam, Beerinder S Karir, Scott T Tagawa
Progress in the understanding of molecular events of carcinogenesis and cancer evolution as well as the identification of tumor antigens has led to the development of different targeted therapeutic approaches, including the use of monoclonal antibodies (mAbs). Prostate cancer (PC) is highly amenable to mAb targeting given the existence of prostate-specific targets and the natural history and localization of metastatic disease. Areas covered: Several aspects of the PC phenotype, including growth factors, angiogenesis mediators, bone microenvironment signals, and immune evasion pathways, have become areas of ongoing investigation in terms of mAb targeting...
November 20, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27817215/biological-therapy-targeting-the-il-23-il-17-axis-in-inflammatory-bowel-disease
#4
Bram Verstockt, Gert Van Assche, Séverine Vermeire, Marc Ferrante
As many inflammatory bowel disease (IBD) patients do not benefit from long-term anti-tumour necrosis factor treatment, new anti-inflammatories are urgently needed. After the discovery of the interleukin (IL) 23/17 axis being pivotal in IBD pathogenesis, many different compounds were developed, targeting different components within this pathway. Areas covered: A literature search to March 2016 was performed to identify the most relevant reports on the role of the IL-23/IL-17 axis in IBD and on the different molecules targeting this pathway...
November 18, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27802061/the-importance-of-correctly-timing-cancer-immunotherapy
#5
Elham Beyranvand Nejad, Marij J P Welters, Ramon Arens, Sjoerd H van der Burg
The treatment options for cancer-surgery, radiotherapy and chemotherapy-are now supplemented with immunotherapy. Previously underappreciated but now gaining strong interest are the immune modulatory properties of the three conventional modalities. Moreover, there is a better understanding of the needs and potential of the different immune therapeutic platforms. Key to improved treatment will be the combinations of modalities that complete each other's shortcomings. Area covered: Tumor-specific T-cells are required for optimal immunotherapy...
November 16, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27845852/platelet-rich-plasma-a-source-of-autologous-growth-factors-and-biomimetic-scaffold-for-peripheral-nerve-regeneration
#6
Mikel Sánchez, Eduardo Anitua, Diego Delgado, Peio Sanchez, Roberto Prado, Gorka Orive, Sabino Padilla
In mammals, axons of injured peripheral nerves (PNI) can and do regenerate, but often the functional recovery is incomplete or suboptimal. In recent years, in vivo tissue engineering approaches through molecular intervention and scaffolding are offering promising outcomes. Evidence is accumulating in both preclinical and clinical settings indicating that platelet rich plasma (PRP) and fibrin scaffolds obtained from this technology hold an important adjuvant therapeutic potential. Areas covered: This review addresses current molecular and cellular data in intrinsic nerve repair processes and describes different strategies to harness and enhance these processes by using biochemical and biomechanical cues...
November 15, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27817204/golimumab-for-the-treatment-of-axial-spondyloarthritis
#7
Carlo Palazzi, Salvatore D'angelo, Michele Gilio, Pietro Leccese, Angela Padula, Ignazio Olivieri
Anti-TNF drugs have represented an epochal revolution in the treatment of rheumatoid arthritis and spondyloarthritis. In the field of axial spondyloarthritis, golimumab, a fully human monoclonal anti-TNFα administered subcutaneously every 4 weeks, has shown significant efficacy and good safety in patients with ankylosing spondylitis. More recently, it was also indicated as an effective treatment for patients suffering from non-radiographic axial spondyloarthitits. Areas covered: A systematic literature search was completed, using the largest electronic databases (Medline, Embase and Cochrane), with the aim to review all data concerning the administration of golimumab in patients suffering from axial spondyloartritis...
November 9, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27805430/injectable-biomaterials-for-stem-cell-delivery-and-tissue-regeneration
#8
Zhanpeng Zhang
Organ dysfunction and failure are major health issues affecting millions of patients, many of whom are desperate for organ transplantation. Tissue regeneration aims at providing alternative solutions through innovative application of cell biology and materials engineering to clinical practice. Biomaterials play a critical role in tissue engineering, which interface with both cell biology and surgical procedures. Injectable stem cell carriers represent a promising platform to harvest the therapeutic effects of cells and to simplify the surgical process...
November 9, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27740858/non-viral-nucleic-acid-delivery-methods
#9
Igor Slivac, David Guay, Mathias Mangion, Juliette Champeil, Bruno Gaillet
Delivery of nucleic acid-based molecules in human cells is a highly studied approach for the treatment of several disorders including monogenic diseases and cancers. Non-viral vectors for DNA and RNA transfer, although in general less efficient than virus-based systems, are particularly well adapted mostly due to the absence of biosafety concerns. Non-viral methods could be classified in two main groups: physical and vector-assisted delivery systems. Both groups comprise several different methods, none of them universally applicable...
November 9, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27805416/translational-development-of-splice-modifying-antisense-oligomers
#10
S Fletcher, M I Bellgard, L Price, A P Akkari, S D Wilton
Antisense nucleic acid analogues can interact with pre-mRNA motifs and influence exon or splice site selection and thereby alter gene expression. Design of antisense molecules to target specific motifs can result in either exon exclusion or exon inclusion during splicing. Novel drugs exploiting the antisense concept are targeting rare, life-limiting diseases; however, the potential exists to treat a wide range of conditions by antisense-mediated splice intervention. Areas covered: In this review, the authors discuss the clinical translation of novel molecular therapeutics to address the fatal neuromuscular disorders Duchenne muscular dystrophy and spinal muscular atrophy...
November 2, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27657737/autologous-hematopoietic-cell-transplantation-in-multiple-sclerosis
#11
Simon M Bell, Basil Sharrack, John A Snowden
Autologous haematopoietic cell transplantation (AHCT) is an evolving treatment avenue in multiple sclerosis (MS), which may be highly effective in controlling disease activity and improving disability. However, AHCT is associated with intrinsic toxicities and risks compared with conventional therapies. With growing experience in patient selection and treatment delivery, AHCT is increasingly considered an option in patients with aggressive disease that's responding poorly to disease modifying therapy. Areas covered: This article provides an introduction to AHCT and looks at its development as a treatment for MS over the last 20 years...
October 14, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27737561/translating-antibody-directed-enzyme-prodrug-therapy-adept-and-prospects-for-combination
#12
Surinder K Sharma, Kenneth D Bagshawe
The generation of cytotoxic drugs, selectively within tumours, from non-toxic prodrugs by targeted enzymes provides a powerful system for cancer therapy. In the form of Antibody directed enzyme prodrug therapy (ADEPT), this approach has shown feasibility in the clinic. Areas covered: Although numerous enzyme prodrug combinations have been reported over the last two decades, only the CPG2 ADEPT system has progressed to clinical trials. Using readily available components such as chemical antibody enzyme conjugate or recombinant multifunctional fusion protein, delivery of a specific enzyme to tumours, its elimination from non-tumour sites and prodrug activation has been achieved with therapeutic benefit in the clinic...
October 13, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27677385/albiglutide-a-unique-glp-1-receptor-agonist
#13
Marc S Rendell
Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. Area covered: The pharmacokinetic and pharmacodynamic properties of albiglutide and its clinical effects are discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Albiglutide has a chemical structure quite distinct from that of other marketed GLP-1 RAs. The agent has less gastrointestinal side effects than other comparable GLP-1 RAs and is safe in patients with renal failure...
October 3, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27666115/the-design-of-clinical-trials-to-support-the-switching-and-alternation-of-biosimilars
#14
Freddy Faccin, Paul Tebbey, Emily Alexander, Xin Wang, Lu Cui, Teotonio Albuquerque
INTRODUCTION: Loss of exclusivity for biological therapeutics opens the door for biosimilar development. Biosimilars must demonstrate structural, functional, and clinical similarity with a currently approved biological originator product. A therapeutic alternative for biologic-naive patients, a single switch from an originator to biosimilar has also been studied in clinically stable patients; further, switching therapy multiple times (alternating) between an originator and a biosimilar has been investigated...
September 27, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27654705/corrigendum
#15
(no author information available yet)
No abstract text is available yet for this article.
September 22, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27616561/present-and-future-of-biologic-drugs-in-primary-sj%C3%A3-gren-s-syndrome
#16
Domenico Sambataro, Gianluca Sambataro, Ylenia Dal Bosco, Riccardo Polosa
INTRODUCTION: Primary Sjögren's (pSS) syndrome is a chronic, autoimmune, and systemic disease characterized by xerostomia, xerophthalmia, muscle pain and fatigue. The disease may be complicated by a systemic involvement, such as a pulmonary fibrosis or the development of lymphoma which severely worsens the prognosis. Actually, there are no recommendations for the management of pSS. However, recent advances in the understanding of its pathogenesis have uncovered some pathways that have potential as therapeutic targets...
September 20, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27602429/intralesional-and-systemic-immunotherapy-for-metastatic-melanoma
#17
Carrie Luu, Nikhil I Khushalani, Jonathan S Zager
INTRODUCTION: Immunotherapy has revolutionized the treatment of metastatic melanoma and dramatically improved patient outcomes. Ipilimumab, an inhibitor of cytotoxic T-lymphocyte antigen-4 (CTLA-4), was the first immunotherapeutic agent to demonstrate improved survival in advanced melanoma. More recently, other immune checkpoint inhibitors, including the programmed death-1 (PD-1) inhibitors pembrolizumab and nivolumab, have demonstrated efficacy in locally advanced unresectable and metastatic melanoma...
September 20, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27871200/denosumab-targeting-the-rankl-pathway-to-treat-rheumatoid-arthritis
#18
Yahui Grace Chiu, Christopher T Ritchlin
Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by focal pathologic bone resorption due to excessive activity of osteoclasts (OC). Receptor activator of nuclear factor kappa B ligand (RANKL) is essential for the proliferation, differentiation, and survival of OC. Denosumab (DMab) is a humanized monoclonal antibody that binds to RANKL with high affinity and blocks its subsequent association with its receptor RANK on the surface of OC precursors. Area covered: The authors review the molecular and cellular mechanisms underlying therapeutic applications of DMab, provide recent highlights on pharmacology, efficacy and safety of DMab, and discuss the potential of DMab as a novel therapeutic option for the treatment of rheumatoid arthritis...
January 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27744717/the-prospect-of-patritumab-for-treating-non-small-cell-lung-cancer
#19
Hidehito Horinouchi
The mutation or expression of HER family members serves as a therapeutic target for tyrosine kinase inhibitors or monoclonal antibodies in diverse cancers, such as non-small cell lung cancer, breast cancer, gastric cancer, head and neck cancer, colorectal cancer, pancreatic cancer and glioblastoma. HER3, which heterodimerizes with HER1 and HER2, has received much attention as a potential target for anti-EGFR treatment. Patritumab is a novel, fully human monoclonal antibody directed against HER3. Areas covered: In this review article, an overview of the market, chemistry, pharmacodynamics, pharmacokinetics, efficacy, and safety of patritumab is provided based on data from phase I studies, a combination phase I trial, and a randomized phase II trial comparing two doses of patritumab...
December 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27737562/ramucirumab-for-the-treatment-of-advanced-or-metastatic-non-small-cell-lung-cancer
#20
Koji Takeda, Haruko Daga
On 12 December 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Areas covered: This review discusses the best treatment strategy for ramucirumab, a vascular endothelial growth factor receptor-2 inhibitor for patients with advanced NSCLC. Expert opinion: The addition of ramucirumab to docetaxel in the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy confers a 1...
December 2016: Expert Opinion on Biological Therapy
journal
journal
39827
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"